EMA and HMA Mark a Key Step with 1st AI Observatory Report
The European Medicines Agency (EMA) recently shared a post on LinkedIn:
”The first AI Observatory report by EMA and the Heads of Medicines Agencies (HMA) summarises the experience gained in hashtag Artificial Intelligence across the EU medicines regulatory network in 2024. The report includes a high-level horizon scanning to identify gaps, challenges and opportunities for integrating AI in medicines regulation.
Key observations:
- AI is increasingly being used through the medicine’s lifecycle, especially in the pre-authorisation stage, with a broad scope of applications to gain insights and support decision making
- By 2024, EMA had been involved in 7 processes to qualify AI tools for medicine development and in 4 scientific advice procedures related to AI
- The network plans to use AI to automate processes and enhance systems or personal productivity – 27 AI tools were reported in 2024, of which 14 were from national agencies.
The AI Observatory was launched as part of the multi-annual AI workplan by the HMA-EMA Network Data Steering Group. The aim is to leverage safe and responsible use of AI for the benefit of public and animal health in the EU.”
The EMA and Heads of Medicines Agencies (HMA) have released their first AI Observatory report, summarizing AI use in the EU medicines regulatory network in 2024.
AI is increasingly applied in medicine development, especially before authorisation, with EMA engaging in 7 AI qualification and 4 scientific advice procedures last year.
The network reported 27 AI tools, including 14 from national agencies, to automate processes and enhance productivity.
The Observatory, part of the HMA-EMA AI workplan, aims to ensure the safe and responsible use of AI in medicines regulation.
Hemostasis Today: Your Daily Brief on Key Medical Developments.
-
Jul 13, 2025, 15:33ISTH Now Accepting Applications for SSC Leadership Roles
-
Jul 13, 2025, 15:32Last Chance to Apply: EHA Preceptorship on Precision Hematology in Germany!
-
Jul 11, 2025, 19:14ISTH 2025 for Cardiac Surgery: LEX-211 (FARES-II) Trial Shows Promising Results
-
Jul 11, 2025, 16:48GPAS 2025: Shaping the Future of Bleeding Disorder Care
-
Jul 10, 2025, 11:23HTRS Thanks CSL Behring for Its Ongoing Commitment to Research Support
-
Jul 13, 2025, 18:182025 ASH ISTH NBDF WFH monitoring report Confirms Strength of 2021 VWD Diagnosis and Management Guidelines
-
Jul 13, 2025, 17:57Preventing VTE in Cancer, Maintaining Low Bleeding Risk: Reduced-Dose Apixaban
-
Jul 13, 2025, 17:172024 NHLBI Workshop Charts Promising Future Directions for ECMO-Induced Coagulopathy
-
Jul 13, 2025, 16:483-Factor Prediction Tool Targets Inactivity After Stroke to Prevent Recurrent Heart Events
-
Jul 12, 2025, 16:21Richard Buka։ Evolution’s Imprint on Blood, Natural Selection Shaping Today’s Hematologic Disorders
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 13, 2025, 15:35World’s First Liver Transplant for Plasminogen Deficiency Performed at KFSHRC
-
Jul 7, 2025, 17:08Detecting Anti-Drug Antibodies to Emicizumab: A French Center’s Remarkable Experience
-
Jul 6, 2025, 21:00From Untouchable to Editable: How 21st-Century Gene Editing Breakthroughs Clash with Systemic Barriers
-
Mar 6, 2025, 17:15Olympus Announces Launch of Single-Use Hemostasis Clip
-
Jul 10, 2025, 18:25Dr. Carol Kasper: Honoring the Legacy
-
Jul 8, 2025, 08:26ASH and HVO Collaborate to Expand Hematology Training in LMICs
-
Jul 6, 2025, 15:02Patients as Experts: EHC Calls for Early Involvement in HTA Systems
-
Jul 6, 2025, 14:56Missed ISTH 2025? Congress Daily Has You Covered
-
Jul 6, 2025, 11:48Japan's Youth Engagement in Hemophilia Care: Where Even the Doctors Get It – HABIT Summit 2025